The 20th Congress of the European Hematology Association took place June 11-14, 2015, in Vienna, Austria.

HSCT outcomes ‘encouraging’ in JAKi responders

Print Friendly, PDF & Email


HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
HSCT preparation
Photo by Chad McNeeley

Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond well to JAK inhibitors, according to researchers. The group found that patients with the best response to JAK inhibition had a 2-year survival probability of 91% after HSCT, compared to 32% for patients... [Read Article]

Print Friendly, PDF & Email

PI3Kδ/γ inhibitor generates rapid responses in CLL

Print Friendly, PDF & Email


CLL_BM.jpg
Micrograph showing CLL

New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve patients with chronic lymphocytic leukemia (CLL). The 18 patients in the expansion cohort of a phase 1 study of duvelisib had a median time to response of 3.7 months, according to iwCLL response... [Read Article]

Print Friendly, PDF & Email

Agent reduces fibrosis, improves platelet counts in MF

Print Friendly, PDF & Email


EHA2015_Messe Wien-rev-240.jpg
Messe Wien, site of EHA 2015

The immunotherapeutic agent PRM-151, when given alone or in combination with ruxolitinib, can reduce bone marrow fibrosis and improve platelet counts in patients with myelofibrosis (MF), results of a phase 2 trial suggest. Using a novel assessment technique known as computer-assisted image analysis (CIA), researchers found that... [Read Article]

Print Friendly, PDF & Email

Combo shows promise for heavily pretreated MM

Print Friendly, PDF & Email


angiogenesis_Credit_Louis_Heiser_&_Robert_Ackland_220.jpg
Angiogenesis
Image by Louis Heiser
and Robert Ackland

Combining a novel agent with dexamethasone can produce successful results where other treatments have failed, according to a presentation at the 20th Congress of the European Hematology Association. Researchers tested low-dose dexamethasone in combination with melflufen, a peptidase-targeted therapy and antiangiogenic compound, in a phase... [Read Article]

Print Friendly, PDF & Email

Activin receptors continue to show efficacy in ß-thalassemia

Print Friendly, PDF & Email


EHA2015_attendee_brt_strt_220.jpg
Attendees at the 20th
Congress of the European
Hematology Association

Two very similar activin receptors, luspatercept and sotatercept, continue to show efficacy in patients with ß-thalassemia, according to research presented at the 20th Congress of the European Hematology Association. The “twin compounds” basically differ from each other in the receptor type, but... [Read Article]

Print Friendly, PDF & Email

Drug won’t advance to phase 3 in ß-thalassemia

Print Friendly, PDF & Email


thalassemia_blood_smear_230.jpg
Blood smear showing
thalassemia

Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia. However, the companies developing the drug have decided not to advance sotatercept to phase 3 trials in this patient population. Instead, the companies are initiating a phase 3 program with sotatercept’s “twin” activin... [Read Article]

Print Friendly, PDF & Email

Jury still out on combo for elderly AML

Print Friendly, PDF & Email


doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor and patient
Photo courtesy of NIH

A 2-drug combination can produce complete responses (CRs) in elderly patients with newly diagnosed acute myeloid leukemia (AML), but whether the treatment confers a survival benefit remains to be seen. The combination consists of the HDAC inhibitor pracinostat and the antineoplastic agent azacitidine. In a phase... [Read Article]

Print Friendly, PDF & Email

Triplet can provide clinical benefit in rel/ref MM

Print Friendly, PDF & Email


multiple_myeloma_240.jpg
Micrograph showing MM

Combination therapy consisting of the HDAC6 inhibitor ricolinostat, pomalidomide, and dexamethasone can provide a clinical benefit for patients with relapsed and refractory multiple myeloma (MM), according to a researchers. In a phase 1b/2 trial, the triplet produced an overall response rate (ORR) of 29% and a clinical benefit rate of 50%. The... [Read Article]

Print Friendly, PDF & Email

Combo delays progression in relapsed CLL

Print Friendly, PDF & Email


CLL_BM.jpg
Micrograph showing CLL

Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some outcome measures in patients with relapsed chronic lymphocytic leukemia (CLL), when compared to fludarabine and cyclophosphamide alone (FC). Patients who received OFC had a significantly higher overall response rate and longer median... [Read Article]

Print Friendly, PDF & Email